This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Devineni, D. Articles by Gallo, J. M. Search for Related Content PubMed PubMed Citation Articles by Devineni, D. Articles by Gallo, J. M.

Uptake of Temozolomide in a Rat Glioma Model in the Presence and Absence of the Angiogenesis Inhibitor TNP-470¹

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

The angiogenic phenotype is associated with hyperpermeable capillaries. Through treatment with angiogenesis inhibitors capillary permeability may be reduced, and it can be anticipated that cytotoxic agents coadministered may be adversely affected. The current investigation examined this possibility for the combination of TNP-470, an angiogenesis inhibitor, and temozolomide (TMZ), a DNA-alkylating agent with demonstrated activity in brain tumors. TNP-470 (30 mg/kg) was given s.c. on days 6, 8, 10, 12, and 14 following s.c. implantation of rat C6 glioma cells in Sprague-Dawley rats. On the 15th day following tumor implantation, control (no TNP-470) and treated rats received 40 mg/kg of TMZ intraarterially. Prior to dosing, a linear microdialysis probe was placed in the tumor to collect interstitial fluid. Plasma and interstitial fluid samples were collected for 8 h and measured for TMZ by a high-performance liquid chromatography assay. Pharmacokinetic parameters for TMZ were calculated by noncompartmental methods. Total systemic clearance (39.8 ± 7 versus 44.2 ± 14 ml min^-1 kg^-1) and volume of distribution (5.4 ± 2 versus 5.2 ± 0.8 L kg^-1) were not significantly different in control and TNP-470-treated animals. However, the mean TMZ area under the interstitial fluid concentration-time curve was reduced by 25% in the TNP-470-treated group compared to the control (5450 ± 1892 versus 4120 ± 1790 µg min ml^-1; P < 0.05). It appears that TNP-470 caused this reduction in the tumor uptake of TMZ by its pharmacodynamic action on the tumor vasculature. Since combination regimens using angiogenesis inhibitors and cytotoxic drugs will be increasingly used, pharmacokinetic and pharmacodynamic investigations will be needed to determine how such combinations can be used effectively. The current animal model, which utilized tumor microdialysis, can serve as a model to further analyze combination chemotherapy.

¹ This project was supported by Grant IRG-191 from the American Cancer Society.

² To whom requests for reprints should be addressed, at Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111.

Received 2/12/96. Accepted 3/18/96.

This article has been cited by other articles:

				M. R. Horsman and D. W. Siemann Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies Cancer Res., December 15, 2006; 66(24): 11520 - 11539. [Abstract] [Full Text] [PDF]

				R. K. Benjamin, F. H. Hochberg, E. Fox, P. M. Bungay, W. F. Elmquist, C. F. Stewart, J. M. Gallo, J. M. Collins, R. P. Pelletier, J. F. de Groot, et al. Review of microdialysis in brain tumors, from concept to application: First Annual Carolyn Frye-Halloran Symposium Neuro-oncol, January 1, 2004; 6(1): 65 - 74. [Abstract] [PDF]

				J. Ma, S. Li, K. Reed, P. Guo, and J. M. Gallo Pharmacodynamic-Mediated Effects of the Angiogenesis Inhibitor SU5416 on the Tumor Disposition of Temozolomide in Subcutaneous and Intracerebral Glioma Xenograft Models J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 833 - 839. [Abstract] [Full Text] [PDF]

				J. Ma, S. Pulfer, S. Li, J. Chu, K. Reed, and J. M. Gallo Pharmacodynamic-mediated Reduction of Temozolomide Tumor Concentrations by the Angiogenesis Inhibitor TNP-470 Cancer Res., July 1, 2001; 61(14): 5491 - 5498. [Abstract] [Full Text] [PDF]

				D. S. Middlemas, C. F. Stewart, M. N Kirstein, C. Poquette, H. S. Friedman, P. J. Houghton, and T. P. Brent Biochemical Correlates of Temozolomide Sensitivity in Pediatric Solid Tumor Xenograft Models Clin. Cancer Res., March 1, 2000; 6(3): 998 - 1007. [Abstract] [Full Text]

				J. H. Sampson, G. E. Archer, A. T. Villavicencio, R. E. McLendon, A. H. Friedman, W. R. Bishop, D. D. Bigner, and H. S. Friedman Treatment of Neoplastic Meningitis with Intrathecal Temozolomide Clin. Cancer Res., May 1, 1999; 5(5): 1183 - 1188. [Abstract] [Full Text] [PDF]